A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 43
- 试验地点
- 8
- 主要终点
- The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon®
研究概览
简要总结
Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results to four times a day Cystagon®.
详细描述
This is a multi-center, open-label, randomized, cross-over study to determine whether steady-state, twice a day treatment with Cysteamine Bitartrate Delayed-release Capsules(RP103) results in comparable depletion of white blood cell (WBC) cystine levels compared to the existing four times a day cysteamine treatment. It will involve up to 20 clinic visits plus intermittent home use of the RP103. Most of these clinic visits occur in clusters of 3-4 consecutive days. Eligible patients will be offered enrollment into a long-term follow up study.
Study with completed results acquired from Horizon in 2024.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects must have nephropathic cystinosis.
- •Subjects must be on a stable dose of Cystagon® sufficient to maintain their white blood cell (WBC) cystine level at ≤ 1.0 nmol/half-cystine/mg protein.
- •Subjects must be able to swallow their typically administered Cystagon® capsule with the capsule intact.
- •Within the last 6 months, no clinically significant change in liver function [i.e., ALT, AST, total bilirubin] and renal function [i.e., estimated GFR] at Screening as determined by the Investigator.
- •Subjects with an estimated GFR (corrected for body surface area) > 30 mL/min/1.73m
- •Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from Screening through completion of the study.
- •Subjects must be willing and able to comply with the study restrictions and requirements.
- •Subjects or their or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study.
排除标准
- •Subject's age < 6 years old or subject's weight < 21 kg.
- •Subjects with a known history, currently of the following conditions or other health issues that make it, in the opinion of the investigator, unsafe for them to participate: inflammatory bowel disease (if currently active) or have had prior resection of small intestine; Heart disease (e.g., myocardial infarction, heart failure, arrhythmias or poorly controlled hypertension) 90 days prior to Screening; Active bleeding disorder 90 days prior to Screening; Malignant disease within the last 2 years.
- •Patients with a hemoglobin level < 10 g/dL at Screening or a level that, in the opinion of the investigator, makes it unsafe for the subject to participate.
- •Subjects receiving any form of cysteamine medication through a gastric tube.
- •Subjects who are receiving maintenance dialysis or who have had a kidney transplant.
- •Subjects who are on an active kidney transplant list or who are planning to receive a kidney transplant within 3 months of Screening.
- •Subjects with known hypersensitivity to cysteamine or penicillamine.
- •Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or have a positive serum pregnancy screen.
- •Subjects who have a made a blood donation within 30 days of Screening.
- •Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.
研究组 & 干预措施
RP103 Q12H
干预措施: Cysteamine Bitartrate Delayed-release Capsules (RP103) (Drug)
Cystagon® Q6H
干预措施: Cystagon® (Cysteamine Bitartrate) (Drug)
结局指标
主要结局
The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon®
时间窗: 4 weeks after the last subject has completed the study
次要结局
- Comparison of Cysteamine PK Profiles, Steady State Cmax, Between RP103 and Cystagon®.(4 weeks after the last subject has completed the study)
- Comparison of Cysteamine PK Profiles, AUC(0-t), Between RP103 and Cystagon®.(6 hours post dosing for Cystagon®; 12 hours post dosing for RP103.)
- Comparison of Cysteamine PK Profiles, Steady State Tmax, Between RP103 and Cystagon®.(4 weeks after the last subject has completed the study)